

# Katrina A B Goddard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2172365/publications.pdf>

Version: 2024-02-01

46  
papers

1,565  
citations

304743  
22  
h-index

315739  
38  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2806  
citing authors

#	ARTICLE	IF	CITATIONS
1	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
2	The evolving landscape of expanded carrier screening: challenges and opportunities. Genetics in Medicine, 2019, 21, 790-797.	2.4	90
3	A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genetics in Medicine, 2016, 18, 1258-1268.	2.4	89
4	Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer, 2015, 15, 156.	2.6	81
5	A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genetics in Medicine, 2017, 19, 575-582.	2.4	68
6	Awareness and use of direct-to-consumer nutrigenomic tests, United States, 2006. Genetics in Medicine, 2007, 9, 510-517.	2.4	56
7	Dengue hemorrhagic fever is associated with polymorphisms in JAK1. European Journal of Human Genetics, 2010, 18, 1221-1227.	2.8	45
8	Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genetics in Medicine, 2013, 15, 933-940.	2.4	45
9	“Is It Worth Knowing?” Focus Group Participants’ Perceived Utility of Genomic Preconception Carrier Screening. Journal of Genetic Counseling, 2016, 25, 135-145.	1.6	44
10	Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genetics in Medicine, 2013, 15, 721-728.	2.4	40
11	Public Awareness and Use of Direct-to-Consumer Genetic Tests: Results From 3 State Population-Based Surveys, 2006. American Journal of Public Health, 2009, 99, 442-445.	2.7	37
12	Reasons for Declining Preconception Expanded Carrier Screening Using Genome Sequencing. Journal of Genetic Counseling, 2017, 26, 971-979.	1.6	37
13	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine, 2012, 14, 633-642.	2.4	36
14	Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. American Journal of Human Genetics, 2018, 102, 1078-1089.	6.2	35
15	Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen’s Actionability Working Group. Human Mutation, 2018, 39, 1677-1685.	2.5	34
16	Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects. Journal of the National Cancer Institute, 2013, 105, 929-936.	6.3	30
17	Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer, 2015, 121, 3281-3289.	4.1	30
18	Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics, 2004, 5, 121-128.	1.4	27

#	ARTICLE	IF	CITATIONS
19	Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing. Contemporary Clinical Trials, 2017, 53, 100-105.	1.8	26
20	Generating a taxonomy for genetic conditions relevant to reproductive planning. American Journal of Medical Genetics, Part A, 2016, 170, 565-573.	1.2	25
21	Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genetics in Medicine, 2012, 14, 656-662.	2.4	24
22	Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing. Genetics in Medicine, 2017, 19, 803-808.	2.4	24
23	Time Costs for Genetic Counseling in Preconception Carrier Screening with Genome Sequencing. Journal of Genetic Counseling, 2018, 27, 823-833.	1.6	22
24	Patient perspectives on the use of categories of conditions for decision making about genomic carrier screening results. American Journal of Medical Genetics, Part A, 2018, 176, 376-385.	1.2	21
25	Patients' ratings of genetic conditions validate a taxonomy to simplify decisions about preconception carrier screening via genome sequencing. American Journal of Medical Genetics, Part A, 2016, 170, 574-582.	1.2	20
26	The NextGen Study: patient motivation for participation in genome sequencing for carrier status. Molecular Genetics & Genomic Medicine, 2017, 5, 508-515.	1.2	20
27	Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 673-680.	2.5	19
28	It's complicated: criteria for policy decisions for the clinical integration of genome-scale sequencing for reproductive decision making. Molecular Genetics & Genomic Medicine, 2015, 3, 239-242.	1.2	19
29	Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening. PLoS ONE, 2018, 13, e0200139.	2.5	19
30	Beta 2 adrenergic receptor polymorphisms in cystic fibrosis. Pediatric Pulmonology, 2005, 39, 544-550.	2.0	16
31	A Confidenceâ€Limitâ€Based Approach to the Assessment of Hardyâ€Weinberg Equilibrium. Biometrical Journal, 2010, 52, 253-270.	1.0	15
32	Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. Molecular Genetics & Genomic Medicine, 2018, 6, 898-909.	1.2	15
33	Recommended care and care adherence following a diagnosis of Lynch syndrome: a mixed-methods study. Hereditary Cancer in Clinical Practice, 2019, 17, 31.	1.5	14
34	Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Familial Cancer, 2017, 16, 377-387.	1.9	11
35	Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings. Genetics in Medicine, 2018, 20, 1186-1195.	2.4	11
36	Lessons Learned From A Study Of Genomics-Based Carrier Screening For Reproductive Decision Making. Health Affairs, 2018, 37, 809-816.	5.2	10

#	ARTICLE	IF	CITATIONS
37	Utilization of HER2 genetic testing in a multi-institutional observational study. American Journal of Managed Care, 2012, 18, 704-12.	1.1	10
38	HLA-DQA Is Associated with Abdominal Aortic Aneurysms in the Belgian Population. Annals of the New York Academy of Sciences, 2006, 1085, 392-395.	3.8	9
39	Adapting the logical basis of tests for Hardy-Weinberg Equilibrium to the real needs of association studies in human and medical genetics. Genetic Epidemiology, 2009, 33, 569-580.	1.3	9
40	Association mapping by generalized linear regression with density-based haplotype clustering. Genetic Epidemiology, 2009, 33, 16-26.	1.3	6
41	Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Familial Cancer, 2019, 18, 317-325.	1.9	6
42	Density-based clustering in haplotype analysis for association mapping. BMC Proceedings, 2007, 1, S27.	1.6	5
43	Issues in association mapping with high-density SNP data and diverse family structures. Genetic Epidemiology, 2007, 31, S22-S33.	1.3	4
44	Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders. Genetics in Medicine, 2019, 21, 2561-2568.	2.4	4
45	ClinGen's Pediatric Actionability Working Group: Clinical actionability of secondary findings from genome-scale sequencing in children and adolescents. Genetics in Medicine, 2022, 24, 1328-1335.	2.4	4
46	Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system. Hereditary Cancer in Clinical Practice, 2022, 20, 17.	1.5	4